Inhibitory effect of heparin-derived oligosaccharides on secretion on interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes

World Journal of Gastroenterology

Volumn 10, Issue 23, 2004, Pages 3490-3494

  Ji, Sheng Li ^a,b   Cui, Hui Fei ^b   Shi, Feng ^b   Chi, Yan Qing ^c   Cao, Ji Chao ^b   Geng, Mei Yu ^a   Guan, Hua Shi ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN DERIVATIVE; HYDROGEN PEROXIDE; INTERLEUKIN 4; INTERLEUKIN 5; OLIGOSACCHARIDE; PHYTOHEMAGGLUTININ;

ARTICLE; CHEMICAL PROCEDURES; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DEPOLYMERIZATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIC GASTROENTERITIS; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; PERIPHERAL LYMPHOCYTE; STRUCTURE ACTIVITY RELATION; SUPERNATANT; T LYMPHOCYTE;

EID: 9244246251     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i23.3490     Document Type: Article

References (67)

1. Casu B. Heparin structure. Haemostasis 1990; 20(Suppl 1): 62-73
2. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90: 220-223
3. Evans RC, Wong VS, Morris AI, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037-1040
4. Yoshikane H, Sakakibara A, Ayakawa T, Taki N, Kawashima H, Arakawa D, Hidano H. Disseminated intravascular coagulation in an ulcerative colitis case not associated with surgery. Hepatogastroenterology 2000; 47: 1608-1610
5. Cui HF, Jiang XL. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin. World J Gastroenterol 1999; 5: 448-450
6. Ang YS, Mahmud N, White B, Byrne M, Kelly A, Lawler M, McDonald GS, Smith OP, Keeling PW. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1015-1022
7. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1551-1555
8. Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001; 46: 2239-2244
9. Vrij AA, Jansen JM, Schoon EJ, de Bruine A, Hemker HC, Stockbrugger RW. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol Suppl 2001; 234: 41-47
10. Torkvist L, Thorlacius H, Sjoqvist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1323-1328
11. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1403-1409
12. Michell NP, Lalor P, Langman MJ. Heparin therapy for ulcerative colitis? Effects and mechanisms. Eur J Gastroenterol Hepatol 2001; 13: 449-456
13. Day R, Forbes A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 1999; 354: 62-65
14. Wan MX, Liu Q, Wang Y, Thorlacius H. Protective effect of low molecular weight heparin on experimental colitis: role of neutrophil recruitment and TNF-alpha production. Inflamm Res 2002; 51: 182-187
15. Fries W, Pagiaro E, Canova E, Carraro P, Gasparini G, Pomerri F, Martin A, Carlotto C, Mazzon E, Sturniolo GC, Longo G. The effect of heparin on trinitrobenzene sulphonic acid-induced colitis in the rat. Aliment Pharmacol Ther 1998; 12: 229-236
16. Lalani T, Simmons RK, Ahmed AR. Biology of IL-5 in health and disease. Ann Allergy Asthma Immunol 1999; 82: 317-333
17. Jaffe JS, James SP, Mullins GE, Braun-Elwert L, Lubensky I, Metcalfe ED. Evidence fox an abnormal profile of interleukin-4 (IL-4), IL-5, and gamma-interferon (gamma-IFN) in peripheral blood T cells from patients with allergic eosinophilic gastroenteritis. J Clin Immunol 1994; 14: 299-309
18. Lorentz A, Schwengberg S, Mierke C, Manns MP, Bischoff SC. Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease. Eur J Immunol 1999; 29: 1496-1503
19. Madden KB, Whitman L, Sullivan C, Gause WC, Urban JF Jr, Katona IM, Finkelman FD, Shea-Donohue T. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. J Immunol 2002; 169: 4417-4422
20. Fussi F. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained. United States Patent 1981; 4: 108-281
21. Lormeau JC, Petitou M, Choay J, Choay SA. Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them. United States Patent 1998; 35: 770
22. Uzan A, Rhone-Poulenc Rorer SA. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof. United States Patent 1998; 5: 721-849
23. Kristensen HI, Tromborg EM, Nielsen JR, Nielsen JI, Johansen KB, Ostergaard PB. Development and validation of a size exclusion chromatography method for determination of molecular masses and molecular mass distribution in low molecular weight heparin. Thromb Res 1991; 64: 131-141
24. Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, Ra C, Costa JJ, Galli SJ. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 1999; 162: 5455-5465
25. Madden KB, Urban JF Jr, Ziltener HJ, Schrader JW, Finkelman FD, Katona IM. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol 1991; 147: 1387-1391
26. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, Raedler A. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995; 108: 21-33
27. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 1996; 110: 1683-1695
28. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000; 105: 651-663
29. Gharaee-Kermani M, Phan SH. The role of eosinophils in pulmonary fibrosis (Review). Int J Mol Med 1998; 1: 43-53
30. Sharath MD, Merchant ZM, Kim YS, Rice KG, Linhardt RJ, Weiler JM. Small heparin fragments regulate the amplification pathway of complement. Immunopharmacology 1985; 9: 73-80
31. Wright TC Jr, Castellot JJ Jr, Petitou M, Lormeau JC, Choay J, Karnovsky MJ. Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge. J Biol Chem 1989; 264: 1534-1542
32. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221: 719-725
33. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230: 1375-1378
34. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol 1991; 29: 676-679
35. Shieh MT, Spear PG. Herpesvirus-induced cell fusion that is dependent on cell surface heparan sulfate or soluble heparin. J Virol 1994; 68: 1224-1228
36. Head KA, Jurenka JS. Inflammatory bowel disease Part 1: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003; 8: 247-283
37. Aiikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-346
38. Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002; 31: 147-166
39. Prajapati DN, Newcomer JR, Emmons J, Abu-Hajir M, Binion DG. Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflamm Bowel Dis 2002; 8: 192-195
40. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1403-1409
41. Kassis J, Fugere F, Dube S. The safe use of epidural anesthesia after subcutaneous injection of low-dose heparin in general abdominal surgery. Can J Surg 2000; 43: 289-294
42. Ang YS, Mahmud N, White B, Byrne M, Kelly A, Lawler M, McDonald GS, Smith OP, Keeling PW. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1015-1022
43. Katz S. Update in medical therapy in inflammatory bowel disease: a clinician's view. Dig Dis 1999; 17: 163-171
44. Koutroubakis IE, Sfiridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, Kouroumalis EA, Manousos ON. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 190-194
45. Day R, Ilyas M, Daszak P, Talbot I, Forbes A. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 1999; 44: 2508-2515
46. Haslam N, Standen GR, Probert CS. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 1289-1291
47. Torkvist L, Thorlacius H, Sjoqvist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1323-1328
48. Day R, Forbes A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 1999; 354: 62-65
49. McCarty MF. Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier-implications for use of glucosamine in inflammatory disorders. Med Hypotheses 1998; 51: 11-15
50. Korzenik JR, Hsu A, Robert ME. Effect of heparin on dextran sulfate sodium-induced colitis. Dig Dis Sci 1998; 43: 1800-1805
51. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1403-1409
52. Ahmed T, Abraham WM, D'Brot J. Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 1992; 145: 566-570
53. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993; 147: 160-163
54. Chang NS, Intrieri C, Mattison J, Armand G. Synthetic posu78-8Ifatd hyaluronic acid is a potent inhibitor for tumor necrosis factor production. J Leukoc Biol 1994; 55: 74
55. Lantz M, Thysell H, Nilsson E, Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88: 2026-2031
56. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-3258
57. Teixeira MM, Hellewell PG. Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol 1993; 110: 1496-1500
58. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR, Naparstek Y. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990; 20: 493-499
59. Fath MA, Wu X, Hileman RE, Linhardt RJ, Kashem MA, Nelson RM, Wright CD, Abraham WM. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J Biol Chem 1998; 273: 13563-13569
60. Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995; 16: 198-204
61. Jones CA, Williams KA, Finlay-Jones JJ, Hart PH. Interleukin 4 production by human amnion epithelial cells and regulation of its activity by glycosaminoglycan binding. Biol Reprod 1995; 52: 839-847
62. Ghosh TK, Eis PS, Mullaney JM, Ebert CL, Gill DL. Competitive, reversible, and potent antagonism of inositol 1,4,5-trisphosphate-activated calcium release by heparin. J Biol Chem 1988; 263: 11075-11079
63. Ahmed T, Syriste T, Mendelssohn R, Sorace D, Mansour E, Lansing M, Abraham WM, Robinson MJ. Heparin prevents antigen-induced airway hyperresponsiveness: interference with IP3-mediated mast cell degranulation? J Appl Physiol 1994; 76: 893-901
64. Sy MS, Schneeberger E, McCluskey R, Greene MI, Rosenberg RD, Benacerraf B. Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol 1983; 82: 23-32
65. Xie X, Rivier AS, Zakrzewicz A, Bernimoulin M, Zeng XL, Wessel HP, Schapira M, Spertini O. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem 2000; 275: 34818-34825
66. Fryer A, Huang YC, Rao G, Jacoby D, Mancilla E, Whorton R, Piantadosi CA, Kennedy T, Hoidal J. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 1997; 282: 208-219
67. Kariya Y, Kyogashima M, Suzuki K, Isomura T, Sakamoto T, Horie K, Ishihara M, Takano R, Kamei K, Hara S. Preparation of completely 6-O-desulfated heparin and its ability to enhance activity of basic fibroblast growth factor. J Biol Chem 2000; 275: 25949-25958